Tech Company Financing Transactions
NeuroDerm Funding Round
Private investors invested in a $2.5 million Series A venture round for NeuroDerm. The financing was recorded on 7/23/2007.
Transaction Overview
Company Name
Announced On
7/23/2007
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Series A
Investors
Proceeds Purpose
The company's lead product, ND0601, is the first skin patch for the continuous delivery of levodopa, currently under development for treating Parkinson's disease.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3 Pekeris St. Ruhrberg Science Bldg. Bell Entrance Rabin Sci
Rehovot, 7670212
Israel
Rehovot, 7670212
Israel
Phone
Website
Email Address
Overview
NeuroDerm (NASDAQ: NDRM), established in 2004, develops transdermal drugs for the treatment of various CNS diseases. The company's lead product, ND0601, is the first skin patch for the continuous delivery of levodopa, currently under development for treating Parkinson's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ayelet Altman
Chief Marketing Officer
Sheila Oren
Executive Vice President
Tami Yardeni
VP - Human Resources
Anat Nahmany
VP - Product Management
Eran Shor
VP - Regulatory Affairs
Ziva Mesika
Browse more venture capital transactions:
Prev: 7/23/2007: Centerre Healthcare venture capital transaction
Next: 7/23/2007: Solaria venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs